Composition, form of production and packaging
Tablets 1 tab.
hydroxyethyldimethyldihydropyrimidine 250 mg
10 pieces. - packings cellular planimetric (5) - packs cardboard.
50 pcs. - cans (1) - packs cardboard.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2011.
PHARMACHOLOGIC EFFECT
Ximedon accelerates the processes of tissue regeneration and shortens the healing time for the burn surface, improves the engraftment of skin grafts with autodermoplasty. Promotes the normalization of the relationship between the content of fibrinogen in the blood and its fibrinolytic activity, improves regional blood circulation. Normalizes the immune system, increases the phagocytic activity of T-lymphocytes and the nonspecific resistance of the organism.
PHARMACOKINETICS
When oral intake of xymedon is a rapid absorption of it for 0.5-1 h; C max of the drug in the blood serum is achieved after 1.7 hours. T 1/2 of the preparation is 5.5 hours. As a result of low percentage of binding to serum albumin (9%) and lack of biotransformation in the body, the drug does not have a competitive effect with other medications.
INDICATIONS
- Deep and superficial burns (preparation of patients for autodermoplasty);
- infected wounds;
- trophic ulcers.
DOSING MODE
Inside, before eating 0.5 g 3-4 times a day. The course of treatment is from 1 to 5 weeks.
SIDE EFFECT
Possible - dyspepsia, allergic reactions.
CONTRAINDICATIONS
- leukemia (acute and chronic);
- Erythremia;
hypersensitivity.
OVERDOSE
Due to the low toxicity and wide latitude of the therapeutic effect of xymedon, no cases of toxic manifestations were observed.
DRUG INTERACTION
Incompatibility of Xymedon with any medications has not been identified.
TERMS OF RELEASE FROM PHARMACY
On prescription.
TERMS AND CONDITIONS OF STORAGE
List B. In a dry, protected from light, out of reach of children, at a temperature of no higher than 25 В° C. Shelf life - 2 years.